Seven years since its IPO, Medicilon gives back to its alma mater; marking nine decades of excellence, China Pharmaceutical University(CPU) fosters innovation through talent development.
November 5, 2025 — On the occasion of Medicilon’s seventh anniversary as a listed company and the 90th anniversary of CPU, Medicilon donated RMB 10 million to the China Pharmaceutical University Education Development Foundation. The funds are designated to support educational development at CPU’s School of Life Science and Technology and to advance the university’s broader educational mission, helping cultivate innovative biomedical talent and contribute to the innovation driven upgrading and high quality development of China’s pharmaceutical industry.
The donation ceremony was attended and witnessed by: Jinxi Ding, Vice President of CPU; Bin Di, Director of the Alumni Office and the Education Development Foundation Office; Qinghua Hu, Dean of the School of Life Science and Technology and the School of Biopharmaceutics; Yutao Jiang, Deputy Party Secretary of the School of Life Science and Technology; Jun Yin, Vice Dean of the School of Biopharmaceutics; Hanmei Xu, Professor at the Department of Biotechnology and Marine Pharmacy, School of Life Science and Technology; Wei Guo, Professor at the Department of Protein and Peptide Pharmaceuticals, School of Biopharmaceutics. Representing Medicilon were Dr. Chunlin Chen, Founder, Chairman & CEO; Guokai Chen, Director, Deputy General Manager and Vice President of Investment, Financing & Development; Huashan Chen, Vice President of Human Resources; and Siyu Chen, Director of Marketing.
Deepening University–Industry Collaboration to Strengthen the Foundations of Pharmaceutical Innovation
At the ceremony, Vice President Jinxi Ding delivered the welcome address. On behalf of the university, he extended a warm welcome and sincere gratitude to Dr. Chunlin Chen and the Medicilon team. He noted that over its 90‑year history, CPU has upheld its mission of strengthening the nation through pharmaceutical development, staying focused on pharmaceutical education and research, and continuously cultivating key professionals for national pharmaceutical innovation. Self‑reliance in biopharmaceuticals is built on robust academic foundations, while sustained advancement of universities relies on aligned support from industry. The university will manage the donated funds prudently, bridge talent training and industrial innovation, nurture outstanding pharmaceutical professionals, and jointly contribute to the Healthy China Initiative.
Dr. Chunlin Chen, an alumnus of CPU, has always cherished his alma mater. From his studies and teaching tenure at CPU to founding Medicilon, he has been inspired by the university’s motto: “Mastering professional skills to serve the public.” Amid the ongoing wave of biopharmaceutical innovation, talent underpins the long-term stability of the industry. Fundamental research thrives on campus, while value translation takes place in industry — the two reinforce each other. Having grown within this vibrant industry ecosystem, Medicilon regards supporting higher education and empowering young scholars as an indispensable responsibility. He expressed the hope that this donation will help CPU cultivate innovative talent equipped with scientific expertise and a strong sense of national commitment, fueling high‑quality growth of China’s pharmaceutical sector.
A Sustained Commitment to Educational Philanthropy and All-Round Talent Development
Talent is the wellspring of a thriving industry, and strong education is what makes an industry strong. Having spent more than two decades in pharmaceutical R&D services, Medicilon has established a dedicated education development fund that integrates its corporate strategy with pharmaceutical higher education and talent pipeline building — a practical expression of its social responsibility and its support for high-quality university education.
To date, Medicilon has donated RMB 15 million to Fudan University, RMB 1.5 million to Shanghai University and RMB 1 million to Putian University, steadily improving the research and teaching environment at partner institutions and upgrading educational resources and facilities. Over the years, Medicilon has adopted diverse approaches including scholarship programs, university‑enterprise partnerships, joint research, and internship platforms to connect university training with real‑world industrial demand. It consistently delivers high caliber, application‑oriented and innovative professionals to China’s biopharmaceutical community, advancing pharmaceutical discipline development and enriching the industrial innovation ecosystem.
Medicilon will continue to invest in pharmaceutical education philanthropy, building an end-to-end support system that spans talent cultivation, research innovation and the translation of results. Leveraging its accumulated industrial and research expertise, Medicilon will strengthen the talent base of the biopharmaceutical industry, drive technological breakthroughs and industrial upgrading through talent‑led innovation, and support the high‑quality, sustainable and innovative growth of China’s biopharmaceutical industry.
